CB2 Insights Announces Appointment of Medical Director in Colombia and Enters Market with Cannabis Research Focus
CB2 Insights (CSE:CBII, OTCQB:CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced it is entering the Colombian market to advance medical cannabis research efforts within the country. The focus is to build Colombia’s patient registry and grow the country’s physician network using CB2’s proprietary artificial intelligence based Decision Support Tool and CB2’s Sail, the industry’s first Clinical Trial Data Management System. To achieve these goals, CB2 has appointed Dr. Paola Cubillos, MD, a prominent Colombian naturopathic and integrative medicine physician, as the Company’s Medical Director in Colombia.
Dr. Cubillos was trained and has practiced in both Toronto, Canada and Colombia. Fusing both conventional and naturopathic treatments, she has spearheaded several medical cannabis research efforts at Clinica Las Americas, a highly recognized private hospital in Colombia that belongs to one of the largest healthcare networks in Latin America. Dr. Cubillos has been at the forefront of medical cannabis advancements and physician perception and education throughout Colombia and Latin America.
“There has been solid growth in positive physician perception throughout Colombia, but we are now at an inflection point where cultivators and manufacturers must embrace traditional research protocols to truly commercialize their products in a meaningful way,” said Dr. Paola Cubillos, Medical Director, Colombia, CB2 Insights. “CB2 Insights has become the go-to name for cannabis-focused research programs in the US, Canada and the United Kingdom, and I’m excited to bring that experience to the Colombian market.”
CB2’s Colombian Opportunity
Colombia represents one of the world’s most important emerging medical cannabis markets. Major local and international cultivators and product manufacturers have invested heavily in the Colombian market as of late, including: Canopy Growth, Aphria, Khiron, Medicine Man Technologies and PharmaCielo. Experts have estimated that Colombia could supply as much as two fifths of the world’s cannabis in the future1. CB2 Insights, by way of its new Medical Director, Dr. Cubillos, will look to be the bridge between physician readiness and the substantial product development occurring within Colombia.
The Company will focus its efforts on supporting Licensed Producers, product manufacturers, pharmaceutical companies and other stakeholders in Colombia that require comprehensive research strategies to bring cannabis-based medicines to market. Traditional clinical research has often been a challenge for manufacturers due to regulatory restrictions and lack of clear guidelines to follow traditional product development frameworks, thus diminishing physicians’ willingness to integrate medical cannabis products into traditional treatment plans.
In the immediate-term, the Company will work to build the patient registry within Colombia, grow the network of physicians ready to prescribe medical cannabis within their practice and support stakeholders in the complete management and execution of clinical trials; data which will help to generate safety and efficacy data for local regulatory agencies including INVIMA – Colombia’s National Food and Drug Surveillance Institute. In addition, the Company will launch its proprietary Decision Support Platform to help provide point-of-care education and reference guidelines to physicians seeking to identify cannabis as a treatment option for their patients. CB2 Insights’ tools will enable physicians to follow standardized protocols in assessing, determining and prescribing medical cannabis, including the identification of patient-specific potential risk factors, drug-drug interactions, dosing guidelines and titration schedules.
About CB2 Insights
CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We are a research and technology company, offering a suite of data and technology solutions as a full service clinical CRO, specializing in Phase II, III and IV, post-marketing, observational and experimental trials in a range of therapeutic areas for sponsors worldwide.
CB2 Insights helps industry stakeholders create a strong value story with Real World Evidence, generation of safety and efficacy data, operating in two segments: clinical solutions and data solutions.
For more information please visit www.cb2insights.com.
Forward Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation, statements regarding the opportunity to provide services and software to the U.S. cannabis industry.
Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.
There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.
No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.
Cannabis - Will The Fortune 500 Join The Party?
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
Thoughtful Brands, Inc. (CSE:TBI)(FWB:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands“), an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe, announces that it intends to consolidate its issued and outstanding common shares (“Shares”) at a ratio of ten (10) pre-consolidated Shares to one (1) post-consolidation Share (the “Consolidation
The Company currently has 389,274,701 Shares issued and outstanding. Following the Consolidation there will be approximately 38,927,470 Shares issued and outstanding. No fractional Shares will be issued and any fractions of a Share will be rounded down to the nearest whole number of Shares. The exercise or conversion price and the number of Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted upon Consolidation.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.